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Background: Ambiguity in malignant transformation of glioma has made prognostic diagnosis very challenging.
Tumor malignant transformation is closely correlated with specific alterations of the metabolic profile. Exploration of
the underlying metabolic alterations in glioma cells of different malignant degree is therefore vital to develop
metabolic biomarkers for prognosis monitoring.
Methods: We conducted 1H nuclear magnetic resonance (NMR)-based metabolic analysis on cell lines (CHG5,
SHG44, U87, U118, U251) developed from gliomas of different malignant grades (WHO II and WHO IV). Several
methods were applied to analyze the 1H-NMR spectral data of polar extracts of cell lines and to identify
characteristic metabolites, including principal component analysis (PCA), partial least squares discriminant analysis
(PLS-DA), fuzzy c-means clustering (FCM) analysis and orthogonal projection to latent structure with discriminant
analysis (OPLS-DA). The expression analyses of glial fibrillary acidic protein (GFAP) and matrix metal proteinases
(MMP-9) were used to assess malignant behaviors of cell lines. GeneGo pathway analysis was used to associate
characteristic metabolites with malignant behavior protein markers GFAP and MMP-9.
Results: Stable and distinct metabolic profiles of the five cell lines were obtained. The metabolic profiles of the low
malignancy grade group (CHG5, SHG44) were clearly distinguished from those of the high malignancy grade group
(U87, U118, U251). Seventeen characteristic metabolites were identified that could distinguish the metabolic profiles
of the two groups, nine of which were mapped to processes related to GFAP and MMP-9. Furthermore, the results
from both quantitative comparison and metabolic correlation analysis indicated that the significantly altered
metabolites were primarily involved in perturbation of metabolic pathways of tricarboxylic acid (TCA) cycle
anaplerotic flux, amino acid metabolism, anti-oxidant mechanism and choline metabolism, which could be
correlated with the changes in the glioma cells’ malignant behaviors.
Conclusions: Our results reveal the metabolic heterogeneity of glioma cell lines with different degrees of
malignancy. The obtained metabolic profiles and characteristic metabolites are closely associated with the
malignant features of glioma cells, which may lay the basis for both determining the molecular mechanisms
underlying glioma malignant transformation and exploiting non-invasive biomarkers for prognosis monitoring.
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Table 1 Clinical sources of the glioma cell lines used in
this study
Designation Source (Tumor stage) P53 gene mutation
CHG5 WHO II Unknown
SHG44 WHO II Wild-type [16]
U87 WHO IV Wild-type [17]
U118 WHO IV Mutation [18]
U251 WHO IV Mutation [16]
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Gliomas, which are the most aggressive type of brain tu-
mors, show high morbidity, a high recurrence rate, and
high mortality. Survival from gliomas depends on the
tumor type and grades of malignancy [1]. According to
the World Health Organization (WHO) standards,
gliomas are classified into four malignant grades. WHO
I–II gliomas can be treated with surgery and chemora-
diotherapy, and are generally associated with a survival
time of 5 to 10 years. WHO III-IV gliomas have a sur-
vival time of only 9–12 months, because of the inefficacy
of surgery and chemoradiotherapy. In addition, over 50%
of low-grade gliomas undergo malignant transformation
into high-grade gliomas within 5–10 years during recur-
rence [2,3]. Malignant transformation of a glioma is a
very complex process, which is associated with poor
prognosis and reduced survival times. Hence, there are
ongoing efforts to increase the understanding of glioma
malignant progression.
To date, oncology research has shown that the malig-
nant transformation of a tumor is closely related to cel-
lular metabolism, mainly through the large-scale genetic
and protein analyses [4,5]. Nevertheless, variations in
these upstream events are not sufficient to establish the
molecular mechanisms of cell metabolic changes in gli-
oma malignant progression. Metabolites, downstream of
both transcription and translation, are potentially a
better indicator of enzyme activity [6]. Thus, high-
throughput metabonomics analysis is very helpful to
gain a better understanding of the molecular mecha-
nisms of glioma malignant transformation and to exploit
biomarkers for prognosis monitoring. In the previous
work, MacKinnon et al. performed metabolic profiling
of glioma tissues and their normal counterparts [7]. Re-
cent studies have further highlighted metabolic profiling
of glioma tissues of different grades [8-10]. Despite con-
siderable progress in understanding metabolomics pro-
filing of glioma tissues, ischemia and hypoxia associated
with tissue sample preparation might cause metabolic
degradation, directly affecting the concentrations of
specific metabolites between the low- and high-grade
glioma [9]. As a prerequisite to the analysis of more
complicated tumor tissues, cell lines are the most rele-
vant model systems for exploring metabolic informa-
tion that correlates with their biological characteristics.
Moreover, data generated by metabolic profiling of indi-
vidual cells could be controllable, highly stable, and re-
peatable [11,12]. Despite these advantages, studies of cell
lines are less extensive than metabolic analysis of glioma
tissues.
In the present study, we conducted 1H NMR-based
metabolic profiling of cell lines from glioma tissues of
different malignant grades, focusing on metabolic pro-
files that are relevant to the malignant features. Themalignancy-associated metabolites identified directly
from cell lines’ spectra could be useful to further deter-
mine the molecular mechanisms underlying malignant
transformation, and to provide a rational basis for deve-
loping non-invasive biomarkers for gliomas prognosis
monitoring.
Results
Metabolic profiles analysis of glioma cell lines
The five cell lines used in this study were derived from
glioma tissues of different malignant degrees (shown in
Table 1). Aqueous phase extracts of these cell lines were
subjected to NMR analysis. The NMR spectra acquired
48 hours after seeding are shown in Figure 1. As the 1H
NMR spectra from six or more measurements for each
cell line displayed almost identical spectral profiles, only
one of the replicates is shown in the Figure 1. These
observations indicated that metabolic profiles of the in-
dependently grown cell lines were highly reproducible
under the same culture conditions. The resonance as-
signments of major metabolites in the spectra were per-
formed based on both literature data [13-15] and the
Human Metabolome Database (http://www.hmdb.ca).
As a result, more than 30 metabolites were identified,
which provided adequate information for assessing va-
riations in metabolic profiles within the five cell lines.
To determine the differences in the metabolic profiles
among the five cell lines, we performed principal com-
ponent analysis (PCA) to analyze the normalized 1H
NMR data. The results showed that all samples were
located in the Hotelling’s T2 oval of the 95% confidence
interval, and the cell extracts from the same cell line
clustered together (Figure 2A). Moreover, cell lines
(CHG5, SHG44) from low-grade glioma were separated
from those derived from high-grade glioma (U118, U87
and U251) along the first principal component (PC1).
To confirm the separation of groups from PCA, we uti-
lized the fuzzy c-means clustering (FCM) method to ana-
lysis metabolic profile clustering by calculating
memberships of each feature to each of the user-defined
numbers of clusters. In this method, a membership value
near 1 indicates strong membership and close to 0
indicates weak or no membership. The PCA scores plot
(Figure 2A) provided visual information on the distribution
Figure 1 1H NMR spectra of aqueous metabolites from five glioma cell lines. The spectral regions from 1.0 to 4.5 ppm and 5.5 to 8.5 ppm
are shown. The water region (4.5–5.5 ppm ) was removed.
Figure 2 Metabolic profiles of five glioma cell lines. (A) PCA scores plot for spectral data of aqueous metabolites from five glioma cell lines.
Each data point in ellipse represents a sample with replicates for each cell line. (B) FCM clustering for spectral data from five glioma cell lines. The
cluster number was set at two and the membership values for each cell line were determined. (C) PLS-DA scores plot of the classification model.
(D) The validation plot of the PLS-DA model, generated from the permutation test that was randomly permuted 999 times with the first three
components. The green square is R2Y (cum), which is the explained variance of the model. The blue square is Q2 (cum), standing for the predictive
ability of the model.
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ters could be set to two. When the cluster number was
two, CHG5 and SHG44 were grouped into one cluster
whereas U118, U87 and U251 were grouped together into
another cluster (Figure 2B). We further used projection to
latent structure with discriminant analysis (PLS-DA) to
evaluate the reliability of the two-cluster model and ob-
tained three predictive principal components using the dis-
crimination calculation. We then performed permutation
tests with 999 iterations to assess the possibility of model
over fitting. The obtained parameters were R2X (cum) =
0.560, R2Y (cum) = 0.964, Q2 (cum) = 0.933, which in-
dicated that the model was highly reliable (Figure 2C
and 2D). These results indicated that the two-cluster
model possessed high discrimination and predictive cap-
ability. Notably, the result from the two-cluster model was
fully consistent with the grouping of cell lines based on the
pathological grade of the corresponding glioma tissues.
The comparison of malignant behaviors of glioma
cell lines
After continuous subculture in vitro, the malignant de-
gree of the glioma cell lines could become inconsistent
with the pathological grade of their glioma tissues. ToFigure 3 Malignant features of five glioma cell lines. (A) H&E staining o
in glioma cell lines by IHC staining. (C) Representative images of MMP-9 expr
showing the invasive capability of the glioma cell lines. (E) Comparison of GF
expression by IHC staining scores. (G) Comparison of invasive capability by ce
represent one of three independent experiments. One-way ANOVA was usedfurther identify the diversity of the malignant behaviors
of cell lines in the two groups, we firstly detected
the proliferation abilities of five cell lines and did not
observe significant difference in proliferation abilities
among the cell lines (Additional file 1: Figure S1). Then
we conducted hematoxylin and eosin (HE) staining, im-
munohistochemical staining of GFAP and MMP-9, and
a transwell assay to evaluate the differentiation level and
invasion ability. The HE staining results showed three
major shapes (circle, star and spindle) and obvious atypia
of all these cell lines (Figure 3A). Immunohistochemical
staining of GFAP was used to evaluate the differentiation
level of the glioma cells. As shown in Figure 3B and 3E,
cell lines of the high-grade group (U118, U87 and U251)
had considerably lower GFAP positive expression com-
pared with those of the low-grade group(CHG5 and
SHG44), indicative of lower differentiation levels of cell
lines of the high-grade group. Both the MMP-9 immu-
nohistochemical staining and the transwell experiment
were used to assess the invasion abilities of glioma cells.
The results showed that the cell lines in the high-grade
group possessed a generally higher invasion ability
than those in the low-grade group (Figure 3C, 3D, 3F
and 3G).f the five glioma cell lines. (B) Representative images of GFAP expression
ession in glioma cell lines by IHC staining. (D) Representative images
AP expression levels by IHC staining scores. (F) Comparison of MMP-9
ll numbers. Values represent the mean ± SD in triplicate, and the data
, ***p < 0.001.
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pression levels, and invasion ability indicated that the
cell lines from glioma tissues of different pathological
grades showed obvious variations in malignant behavior.
Compared with the low-grade group, the high-grade
group showed a lower degree of differentiation and
higher invasion ability. Thus, the two-cluster model of
metabolic profiles was closely associated with the malig-
nant behaviors of glioma cell lines cultured in vitro.
Analysis of characteristic metabolites
To identify the characteristic metabolites responsible for
the separation between the low-grade group and the
high-grade group, we applied OPLS-DA to analysis the
difference in metabolic profiles of cell lines in the two
groups. The scores and loading plots with correlation
coefficients are shown in Figure 4A. The loadings plot
was used to identify the significant characteristic meta-
bolites responsible for the clustering patterns. ResonanceFigure 4 Analysis of characteristic metabolites significantly responsible
score plot and OPLS-DA loading plot. The low-grade group includes CHG5
The loading profile corresponds to tp1. The color of the loading plot can b
The red color indicates that the variables are very significant (|r| > 0.463 and
|r| < 0.463 and VIP > 1); and blue indicates that the variables are not signific
VIP score from PLS-DA shown in the figure was the average across all the s
characteristic metabolites between the low-grade and the high-grade grouassignments of these characteristic metabolites were ac-
cording to literature references and the human meta-
bolome database (http://www.hmdb.ca). Approximately
17 characteristic metabolites were identified (Table 2),
including: leucine (Leu), valine (Val), isoleucine (Ile),
lysine (Lys), glutamate (Glu), glutamine(Gln), glutathione
(GSH), threonine (Thr), tyrosine (Tyr), phenylalanine
(Phe), taurine (Tau), sn-glycero-3-phosphocholine (GPC),
myo-inositol (Myo), creatine (Cr), lactate (Lac), formate
(For) and acetate (Ac).
The importance of the 17 metabolites in distinguishing
metabolic profiles was ranked according to their VIP
scores of the OPLS-DA model (Figure 4B). The results
indicated that taurine had the highest correlation with
the grouping of the glioma cells, followed by glutamine
and lactate.
Additionally, we calculated the relative integrals of the
characteristic metabolites for the two groups. Compared
with the low-grade group, the high-grade group showedfor distinguishing cell lines between the two groups. (A) OPLS-DA
and SHG44; while the high-grade group includes U87,U251 and U118.
e used to identify the significant variables in the class separation.
VIP > 1); orange indicates that the variables are significant (0.362 <
ant (NS). (B) VIP rank-score of quantified metabolites. The overall
elected components. (C) The comparison of relative intensities of
ps. (Student’s t-test was used, *p < 0.05; ***p < 0.001).
Table 2 Characteristic metabolites from the OPLS-DA
model of 1H NMR analysis of cell lines































































Formate 8.461 s 1.433
Acetate 1.920 s 5.618
Multiplicity: s singlet, d doublet, t triplet, dd doublet of doublets, m multiplet.
VIP: Variable importance in the projection was obtained from OPLS-DA model.
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Cr, Tau, Lac, Ac and For, and significantly increased
levels of other metabolites, including Val, Leu, Ile, Lys,
Glu, Gln, GSH, GPC, Myo, Thr and Tyr (Figure 4C).Correlation analysis of characteristic metabolites
To further clarify the potential relationships among the
characteristic metabolites and the interrupted metabolic
pathways in the two groups, we calculated Pearson’s cor-
relation coefficients of the relative integrals of the charac-
teristic metabolites (Figure 5A). Both the low-grade group
and the high-grade group displayed quite different corre-
lation patterns. Figure 5B show a network connecting the
differently correlated metabolites in the two groups. Both
groups displayed few similar correlations but many dif-
ferent correlations. Positive correlations of the branched
chain amino acids (BCAA, including Ile, Val, Leu) in the
low-grade group were also observed in the high-grade
group. However, BCAAs in the high-grade group showed
positive correlations with glutamine, tyrosine, phenylalan-
ine, GPC; but negative correlation with myo-inositol, glu-
tamate, threonine, glutathione, lactate, which disappeared
in the low-grade group. Moreover, the positive correla-
tions of BCAA with acetate observed in the low-grade
group, disappeared in the high-grade group. Lysine was
negatively correlated with taurine and creatine in the low-
grade group, but disappeared in the high-grade group.
Notably, the correlation patterns of the metabolites in the
high-grade group were significantly different from those
in the low group. Based on the different correlations of
characteristic metabolites and the results from Kyoto
encyclopedia of genes and genomes (KEGG) analysis, we
summarized the potential disordered metabolic pathways
that are associated with the malignant behaviors. As
shown in Figure 6, the disordered metabolic pathways are
mostly involved in TCA cycle anaplerotic flux, amino
acid metabolism, anti-oxidant mechanism and choline
metabolism.
In addition, we utilized the GeneGo pathway analysis
platform to generate a protein-metabolite interactional
network that could associate the characteristic metabolites
with malignant behavior markers GFAP and MMP-9. The
GeneGo analysis platform provides the prebuilt networks
of protein-compound/metabolite assembled by GeneGo
scientific annotators based on proven literature evidence
[19]. Nine of the seventeen metabolites (valine, glutamine,
glutathione, tyrosine, phenylalanine, leucine, acetate,
choline, creatine) could directly connect to GFAP and
MMP-9 pathway networks via the shortest path network
option (Additional file 2: Figure S2). The altered levels of
the nine metabolites were closely associated with the
changed functions of GFAP and MMP-9, suggesting that
these metabolites could be explored as potential bio-
markers for monitoring malignant transformation of
glioma cells.
Discussion
Previous studies have documented the global metabolo-
mic profiling of glioma tissues of different grades and
Figure 5 Analysis of the correlation of the characteristic metabolites in the low-grade and high-grade groups. (A) The heatmap of the
Pearson’s correlation coefficients for characteristic metabolites in the low-grade and high-grade groups. The colors refer to the pair-wise correlation
coefficients ranging from 1 (red) to −1 (blue). (B) Metabolic connectivity identified by the Pearson’s correlation coefficients in the low-grade and
high-grade groups. The red color reflects a positive correlation, while the blue color reflects a negative correlation.
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standing the underlying metabolic alterations associated
with the progression of gliomas. However, researchers
noted the limitation that ischemia and hypoxia causemetabolic degradation in glioma tissues, which could
seriously affect the concentrations of specific metabo-
lites. In the present work, we identified the malignancy-
associated metabolomic signature directly from the
Figure 6 Metabolic pathways of the malignancy-associated
metabolites. Compared with the low-grade group, the relative
intensities of metabolites down-regulated in the high group are
shown in green, whereas those up-regulated are shown in red.
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filing. According to references [1,2], malignant gliomas
(WHO II) and glioblastoma( WHO IV) are the most
typical gliomas involved in malignant transformation.
Thus, our study focused on glioma cell lines derived
from glioblastoma (WHO IV) and WHO II grade gli-
oma. To ensure the high reproducibility and accuracy of
the metabolomic signature, six or more independent
replicates of each cell line were obtained under the same
conditions. The careful selection of cell cultures with the
same growth conditions could ensure no significant
differences among the metabolic profiles caused by the
extracellular environment among the metabolic profiles.
According to the literature [20-22], we used the dif-
ferentiation level and invasion ability to evaluate the
malignant degrees of these cell lines after continuous sub-
culture in vitro. The expression level of GFAP is an im-
portant index to assess the differentiation level of glioma
cells [23]. In addition, previous studies have shown that
MMP-9 plays an important role in the invasion process of
glioma cells [24].The malignant transformation of glioma
cells is accompanied by increased expression of MMP-9
[25]. The measured GFAP and MMP-9 expression levels
showed that the high-grade cell lines (U87/U118/U251)
possessed a lower level of differentiation and a higher
invasion ability than the low-grade cell lines (CHG5/
SHG44), indicative of the consistency between the malig-
nant degree of cell lines and the pathology grades of their
glioma tissues after continuous subculture in vitro.
By the unsupervised and supervised analyses of 1H
NMR data for the five glioma cell lines, we found thatthe metabolic profiles of cell lines CHG5 and SHG44
(WHO II)were separated from those of U87,U118 and
U251(WHO IV). The clustering of metabolic profiles
was consistent with the cell lines grouping based on the
pathology grades of their glioma tissues. These findings
indicated a close correlation between the metabolic
profiles of cell lines and their malignant behaviors.
Seventeen characteristic metabolites were identified to
distinguish the metabolic profiles of the cell lines. The
metabolic profiles from cell lines might provide informa-
tion associated with their malignant features and other
biological features; therefore, we further investigated the
correlation of these characteristic metabolites with the
glioma malignant behavior markers GFAP and MMP-9.
Nine characteristic metabolites were directly connected
to the GFAP and MMP-9 pathway network, including
Val, Glu, GSH, Tyr, Phe, Leu, Ace, GPC and Cr. The
levels of metabolites Val, Glu, GSH, Tyr, Leu and GPC
significantly increased, while those of other three meta-
bolites Ace, Cr and Phe decreased in the high-grade
group. It seems that the altered levels of these metabo-
lites could be associated with the differentiation and in-
vasion process of glioma cells.
Notably, most of these altered metabolites in the two
groups were amino acids. The altered amino acids in the
tumor are mostly involved in TCA cycle anaplerosis [13]
and protein biosynthesis [26]. It has been reported that
Phe, Tyr, Leu and Val are involved in anaplerosis, which
enter the TCA cycle by being converted into fumarate
and succinyl CoA, respectively [27]. Moreover, glutam-
ine is involved in anaplerosis through glutaminolysis,
which enters the TCA cycle by being converted into glu-
tamate initially and then into α-ketoglutarate [28]. Even
though, the level of Phe was decreased, the amino acids
including Val, Gln, Tyr, Leu were generally up- regulated
in the high group, suggesting that more active TCA cycle
anaplerotic flux might occur during malignant trans-
formation of glioma cells.
In addition to increased amino acids, a higher level of
GPC in the high-grade group was observed. As one of
important choline-containing metabolites, GPC is in-
volved in choline phospholipid metabolism of cell mem-
branes. Alterations in choline phospholipid metabolism,
with consequent alterations of these choline-containing
metabolites, are a common feature of the cancer [29].
Thus, the increased level of GPC in the high-grade
group might be related to the biosynthesis of cell mem-
branes for rapid growth and high invasion ability. The
metabolite GSH was also up-regulated in the high-grade
group. As a ubiquitous intra- and extracellular protective
antioxidant, GSH plays a key role in reducing reactive
oxygen species and combating increased oxidative stress.
A previous study reported that the level of reactive oxy-
gen species in cancer cells was associated with malignant
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in protecting cells from radiation damage, which has
generated reactive oxygen species. Rosi et al. found that
a high level of GSH was correlated with radiation-
induced apoptosis by MR spectra of cultured tumor cells
[31]. Thus, consistently with previous literature [30,31],
the elevated GSH levels observed in our work might be
related to enhanced antioxidant mechanisms in glioma
cells with high malignant degree.
Decreased levels of creatine and acetate were observed
in the high group. Both metabolites are usually detected
in magnetic resonance imaging research of brain tumors.
The creatine level reflect energy buffering and transport.
Several studies have suggested that the creatine level in
the low-grade gliomas is almost identical to that in the
high-grade gliomas [29,32]. Nonetheless, some studies
observed that decreased creatine levels in brain tumors
and in rectal cancer tissues at different stages [33,34]. So
far, the importance of creatine levels has remained un-
clear in the differentiation of low –grade from high-
grade tumors [35]. The down-regulation of creatine
observed in our work might support its biological im-
portance in glioma grading. Acetate can either be trans-
formed into acetyl-CoA, entering the TCA cycle, or be
used as a precursor of membrane fatty acids [36], Never-
theless, the exact function of acetate in tumor cells
remains unknown. Thus, the reason why acetate wa
down-regulated in glioma cell lines in the high-grade
group requires further investigations.
The other metabolites, including lactate, taurine, myo-
inositol, lysine, isoleucine, threonine, formate, were not
mapped into the GFAP/MMP-9 pathway network. How-
ever, some of them, such as lactate, taurine, myo-
inositol, are metabolic markers frequently reported in
cancers. Increased levels of lactate were detected in
stomach cancer, oral cancer and rectal cancer tissues
compared with the relevant normal tissues [34]. Interes-
tingly, the decreased level of lactate was observed in cells
of head and neck squamous cell carcinoma, compared
with those of normal human oral keratinocytes. We also
found a decreased lactate level in glioma cell lines in the
high-grade group. Lactate production, due to the high
glycolytic rates in cancer cells, enhances intracellular
acidosis, which in turn leads to apoptosis. Previous
works [37,38] have also demonstrated that glioma cells
could rapidly discharge lactate into the nearby micro-
environment through monocarboxylate transporters.
Thus, the lactate down-regulation observed in this
work might be associated with the anti-apoptotic
ability of glioma cells. Furthermore, taurine and myo-
inositol are associated with osmo-regulation and vo-
lume regulation [13]. In our study, the levels of taurine
and myo-inositol in the two groups were significantly
different, implying that these metabolites might beinvolved in osmoregulation and volume regulation of
glioma cells.
To the best of our knowledge, this is the first study to
explore the malignancy-associated metabolic signature
of on glioma cell lines with different malignant degrees
using NMR-based metabolomic analysis. Consistent with
other studies [14,39], our results provide evidence that
metabonomics analysis of cultured tumor cells is a valid
method to understand the metabolic alterations account-
able for their biological properties. Although we found
that the characteristic metabolites are significantly asso-
ciated with the malignant features of glioma cell lines,
future works should be performed to further understand
the regulation mechanism of the characteristic metabo-
lites in malignant transformation.Conclusions
In the present work, we performed NMR-based metabolo-
mic analysis on glioma cell lines with different malignant
degrees. We have demonstrated that the metabolic pro-
files of the glioma cell lines are significantly associated
with their malignant features. Moreover, we identified
seventeen characteristic metabolites contributing signifi-
cantly to distinguishing the metabolic profiles between the
low-grade group and the high-grade group. These charac-
teristic metabolites are primarily involved in dysregulation
of metabolic pathways, including TCA cycle anaplerotic
flux, amino acid metabolism, anti-oxidant mechanism and
choline metabolism, which could correlate with the al-
tered malignant behaviors of glioma cells. Our results lay
the basis for both determining the molecular mechanisms
underlying glioma malignant transformation and exploi-
ting non-invasive biomarkers for the prognosis of glioma.Materials and methods
Cell lines, cell culture and cell proliferation assay
Five astrocytoma cell lines from glioma tissues with differ-
ent pathological grades (CHG5, SHG44, U87, U118, U251,
Table 1) were used in the present work. Cell lines (CHG5
and SHG44) were kindly provided by Professor XW Bian of
the Third Military Medical University, China. Glioblastoma
U87 and U118 cell lines were obtained from the American
Type Culture Collection (ATCC). Glioblastoma U251 cell
line was obtained by the China Center for Typical Culture
Collection (CCTCC). All the cell lines were maintained in
DMEM supplemented with 100 units/ml penicillin,
100 μg/ml streptomycin and 10% fetal bovine serum (FBS,
Hyclone) at 37°C in a humidified atmosphere of 5% CO2.
Five cell lines plated in 96-well plates (5 × 103 per well)
were cultured for 24 h and 48 h. Cell samples were then
incubated with CellTiter 96 AQueous solution (MTS,
20 μl/well) and culture medium (DMEM, 100 μl/well)
for 4 h. Next, colored MTS products were detected by
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plate Reader (BioTek, USA).
H&E and immunohistochemical stains
Cells were maintained on cover slips of 6-well plates in
DMEM containing 10% fetal bovine serum as described
above. At confluence, cells on cover slips were fixed with
4% paraformaldehyde for 15 min at room temperature,
and were then stained with haematoxylin and eosin.
Immunohistochemistry was performed as follows. Fixed
cover slips were rinsed with 1% normal calf serum in
PBS for 15 min, and permeabilized with 0.3% Triton
X-100/PBS for 15 minutes. The cells were then incu-
bated with primary antibodies specifically against GFAP
(GA-5,MAIXIN-BiO) and MMP-9(56-1A4, MAIXIN-
BiO) at 4°C overnight. The slides were washed with
phosphate buffer solution (PBS) including 0.1% Triton
X-100, incubated with biotinylated anti-mouse antibody
(1:100) at 37°C for 1 hour, incubated with fluorescein
isothiocyanate-labeled streptavidin conjugate (1:100) for
1 hour, and finally washed with PBS including 0.1% Tri-
ton X-100 three times, mounted, and analyzed under a
microscope. The positive cells were counted and scored
at a magnification of × 400 under a light microscope in
five different fields for each coverslips. One-way analysis
of variance (ANOVA) was used to determine the sta-
tistical significance of the differences among the five
cell lines.
Invasion assay
The invasion assay was performed using transwell cell
culture chambers (24 wells, 8-μm pore size; BD Bio-
sciences). 1 × 105 tumor cells were resuspended in
200 μl of serum-free DMEM and added to the corre-
sponding upper inserts, respectively. DMEM (600 μl)
with 10% FBS was added to the lower chamber. After
24 h, invaded cells were fixed and stained with crystal
violet (0.2% in 2% ethanol) for 20 min. Cells on the
upper side of the insert membrane were removed with
cotton rods. The invaded cells were counted at a mag-
nification of × 100 under a light microscope in nine dif-
ferent fields for each insert. The measurements were
repeated at least three times. One-way ANOVA was
used to determine the statistical significance of the dif-
ferences among five cell lines.
Extraction of intracellular metabolites
Before metabolite extraction, 1 × 106 cells were seeded
in 10-cm diameter culture dishes and incubated for 48 h
at 37°C and 5% CO2. About 5 × 10
6 cells were then har-
vested and quenched by a direct cell quenching method,
as described by Teng et al. [40]. Intracellular metabo-
lites were extracted using a dual phase extraction pro-
cedure adopted from Viant et al. [41]. A mixture ofmethanol, chloroform and water in the volume ratio of
4:4:2.85 was used to generate a two-phase extract.
NMR analyses of intracellular extracts
In the present study, only the aqueous intracellular ex-
tracts were used. Before NMR analysis, solvents were
completely removed using a Nitrogen Blowing Concen-
trator. Each aqueous sample was reconstituted in 500 μl
of D2O. Then 50 μl of D2O containing 1.5 M KH2PO4
and 0.1% sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4
(TSP) was added. D2O was used for field frequency lock,
and TSP was used to provide the chemical shift re-
ference (d0.00). Subsequently, all the samples were vor-
texed, and centrifuged at 12000 g for 15 min at 4°C to
remove any insoluble components. Finally the collected
supernatants (500 μl) were transferred to 5 mm NMR
tubes [42].
All 1H NMR experiments were conducted on a Bruker
Avance III 600 MHz spectrometer at 25°C. Solvent-
suppressed 1D NOESY spectra were acquired using the
pulse sequence [(RD)-90°-t1-90°-τm-90°-ACQ]. t1 was
6.6 μs. Water suppression was achieved by irradiation of
the water resonance during the recycle delay ( RD ) of 4 s
and the mixing time (τm) of 120 ms. The spectral width
was 10 kHz with an acquisition time per scan of 1.64 s,
and 256 transients were collected into 32 K data points
for each spectrum. The free induction decay (FID) was
zero-filled to 64 K and an exponential line-broadening
function of 0.3 Hz was applied to the FID before Fourier
transformation. Both phase and baseline corrections were
carefully performed. The 1H NMR spectra were refe-
renced to the methyl group of TSP (δ 0.00).
Multivariate statistical analysis
NMR spectra were reduced to 2587 integrated regions
with a width of 0.003 ppm (bin) corresponding to the
region of δ 9.5-0.8 using the MestRova6.5 software
(Mestrelab Research S.L, Spain). The region of δ 5.5-4.5
was removed to eliminate artifacts related to the residual
water resonance. (The remaining integrals for each
NMR spectra were normalized to the sum of the spectral
intensity to compensate for the differences in sample
concentration) [43].
Before multivariate statistical analysis, the integral
values were mean-centered and pareto-scaled [44]. To
check general separation and identify the outliers, PCA
was performed on NMR data sets of all cell samples
using the SIMCA-P V12.0 software package (Umetrics
AB, Umea, Sweden). Then, PLS-DA and OPLS-DA,
were subsequently used to improve the separation [45].
The PLS-DA model was cross-validated to measure the
robustness by a permutation analysis with 999 times.
FCM is a clustering method that allows one piece of
data to belong to two or more clusters and is extensively
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Where m is any number greater than 1, uik is the de-
gree of membership of xi in the cluster k, xi is the i-th
measured data, vk is the center data of the k cluster. We
used the FCM clustering algorithm through the Fuzzy
Logic Toolbox in MATLAB (Version MATLAB2011b,
MathWorks, USA).
Identification of characteristic metabolites and
quantitative comparison
Two criteria were used to identify the characteristic me-
tabolites. One was the VIP score of the OPLS-DA model
[48] and the other one was the correlation coefficient(r)
of the variable relative to the predictive component(t[1])
in the OPLS-DA model [49]. The critical values of cor-
relation coefficients were determined by the degrees of
freedom in the OPLS-DA model. Characteristic meta-
bolites with a VIP > 1 and |r| > the critical values were
identified.
For relative quantification of characteristic metabolites,
the relative integrals of metabolites were used for com-
parison between two groups. The average changes and
standard error were calculated [43].
System statistical metabolic correlation and network
analysis
Pearsons’s correlation coefficients of cell samples in two
groups were further calculated to display the relation-
ships between the relative integrals of spectral peaks in a
certain biological profile, as described previously [43]. A
heatmap was used to display the correlation matrices.
For all correlations, a p-value was calculated based on a
t-test to check the statistical significance. The signifi-
cance threshold was set to the usual value of 0.05 and








The network of the metabolites with significance cor-
relations was displayed by MATLAB Bioinformatics
toolbox. Significant positive correlations were shown in
red, while significant negative correlations were in blue.
In addition, GeneGo MetaCore was used to analyze the
network that describes the interaction between the cha-
racteristic metabolites and GFAP/MMP-9 [19].Additional files
Additional file 1: Figure S1. The proliferation ability of five glioma cell
lines. Differences in the 490 nm absorbance among five cell lines were
compared by One-way ANOVA. Values represent the mean ± SD in
triplicate.
Additional file 2: Figure S2. Network of the shortest directional paths
leading to characteristic metabolites related to GFAP/ MMP-9 regulation.
Small molecules appear as purple hexagons, reactions as grey boxes,
enzymes as orange shapes, transcription factors as red stars, ligands and
extracellular peptides as green shapes, and transporters as purple “X”
shapes. Metabolites with available data points are tagged with blue
circles. Arrows denote mechanisms of interaction, in which green signifies
activation and red indicates inhibition. Grey interactions represent
transport or consumption/production of metabolic intermediates.
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